Travere Therapeutics Earnings Call Shows Growth Amid Risks

Travere Therapeutics, Inc. ((TVTX)) has held its Q4 earnings call. Read on for the main highlights of the call.

Travere Therapeutics struck a cautiously optimistic tone on its latest earnings call, pointing to record demand for its kidney drug FILSPARI, triple-digit revenue growth and a swing to profitability. Management acknowledged rising costs, regulatory delays and intensifying competition, but argued that strong execution and pipeline progress leave the company on firmer footing heading into 2026.

FILSPARI demand hits record levels

FILSPARI continued to gain traction in IgA nephropathy, with 908 new patient start forms in Q4 2025, the highest quarterly total to date. Management said momentum has carried into early 2026, driven both by new prescribers and deeper adoption among existing physicians, signaling broader community acceptance of the therapy.

FILSPARI drives triple-digit revenue growth

FILSPARI U.S. net product sales reached about $103.3 million in Q4 2025 and $322 million for the full year, translating to 144% year-over-year growth. This rapid ramp underscores the drug’s commercial potential in a still-early IgAN market and cements it as Travere’s primary revenue engine.

Company swings to profitability

Total U.S. net product sales were $126.6 million in Q4 and $410.5 million for full-year 2025, reflecting a broad-based improvement beyond FILSPARI. Travere posted GAAP net income of $2.7 million, or $0.03 per basic share, versus a $60.3 million loss a year earlier, while non-GAAP net income reached $33.3 million, reversing the prior-year deficit.

Regulatory progress in FSGS despite delay

Travere highlighted regulatory progress for FILSPARI in focal segmental glomerulosclerosis, where a supplemental filing is under active FDA review with a new decision date set for April 13, 2026. Despite the schedule change, management expressed confidence in the clinical profile and reiterated its belief that proteinuria reduction can serve as an approvable surrogate endpoint.

Pegtibatinase program restarts in classical HCU

The company has resumed site activations for the pivotal Phase III HARMONY trial and its ENSEMBLE extension after improving the manufacturing process for pegtibatinase. Earlier Phase I/II data from COMPOSE showed about a 67% reduction in total homocysteine levels and durable responses out to one year in some patients, supporting the drug’s potential in classical homocystinuria.

Balance sheet bolstered by milestones

Travere ended 2025 with roughly $322.8 million in cash, cash equivalents and marketable securities, providing a solid liquidity cushion. The Q4 results were helped by about $40 million from a milestone related to CSL, roughly $10 million in proceeds from a Renalys transaction and a separate discontinued-operations milestone, all of which strengthened the balance sheet.

Commercial expansion supports future launches

To support FILSPARI’s growth and a potential FSGS launch, Travere expanded its field-based commercial team from around 80 to more than 100 representatives. The company also emphasized that approximately 96% of patients now have a pathway to reimbursement, which should help sustain uptake even as competition increases.

FDA queries extend FSGS review timeline

The FDA issued a major amendment and sought additional information on the FILSPARI FSGS application, pushing back the agency’s target action date to April 13, 2026. This creates added regulatory timing risk and leaves investors waiting longer for a potential label expansion that could significantly broaden FILSPARI’s addressable market.

SG&A spending rises sharply

Operating leverage remains a key watch point as selling, general and administrative expenses jumped to $101.7 million in Q4 2025, up from $69.5 million a year earlier. On a non-GAAP basis, SG&A climbed to $76.0 million, reflecting heavy investment in commercial infrastructure and launch preparation for a possible FSGS indication.

Gross-to-net pressure weighs on near-term revenue

Management cautioned that gross-to-net discounts on FILSPARI are expected to move into the mid-20% range for 2026, up from about 20% in 2025. Because the first quarter typically carries the steepest discounts, reported Q1 revenue may look softer sequentially even if underlying demand remains strong.

Competitive landscape intensifies in IgAN

New entrants targeting IgA nephropathy, including APRIL and BAFF pathway agents, have begun to establish a foothold, with one rival reporting roughly 500 patient starts since launch. Travere argued that these drugs may help expand the overall market, but acknowledged that switching patterns and payer decisions could introduce headwinds for FILSPARI over time.

Ongoing investment to support growth

The company signaled that operating expenses will rise modestly in 2026 to fund the restarted HARMONY Phase III trial, ensure pegtibatinase supply and continue evidence generation for FILSPARI. Additional commercial spending, including the larger field force, will likely temper near-term margin expansion even as revenues grow.

Guidance highlights cautious confidence

Travere reiterated key metrics, including Q4 FILSPARI sales of about $103.3 million, full-year 2025 FILSPARI revenue of roughly $322 million and total net product sales of $410.5 million, while confirming the new April 13, 2026 target action date for the FSGS filing. For 2026, management expects gross-to-net for FILSPARI to move to the mid-20% range, modest operating expense growth, continued investment in HARMONY and no immediate need to raise additional capital.

Travere’s latest earnings call painted the picture of a company transitioning from story stock to execution story, powered by a rapidly scaling kidney franchise. While higher discounts, rising costs, regulatory delays and new competition introduce volatility, management’s confidence in FILSPARI and pegtibatinase suggests that long-term value creation remains very much in play for patient and investor alike.